[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

Rhea-AI Filing Summary

PTC Therapeutics director Allan Steven Jacobson reported offsetting transactions executed on 10/03/2025 under a written Rule 10b5-1 plan adopted on 03/12/2025. He exercised 12,000 stock options with an exercise price of $30.86, receiving 12,000 shares, and simultaneously sold 12,000 shares at $65.00. After the trades his direct holdings changed to 29,451 shares before the sale and 17,451 shares following the sale; the derivative table shows the option became exercisable on 10/03/2025 and expires on 01/03/2026. The form is filed by one reporting person and was signed by an attorney-in-fact on 10/07/2025.

Insights

Corporate Governance Analyst

Director executed option exercise and contemporaneous sale under a 10b5-1 plan.

The reporting person exercised $30.86-strike options to acquire 12,000 shares and sold an equal number at $65.00 on 10/03/2025, which is consistent with structured trading under a pre-established trading plan. Use of a written Rule 10b5-1 plan typically provides an affirmative defense to insider trading claims when properly adopted and documented.

Key dependencies and items to watch include the plan adoption date 03/12/2025, contemporaneous holdings moving from 29,451 to 17,451 shares, and the option expiration on 01/03/2026. Monitor future Form 4s for additional plan-based activity or changes in beneficial ownership.

Equity Compensation Specialist

Transaction reflects option exercise and immediate monetization of shares.

The option exercise converted 12,000 derivative rights into 12,000 common shares at an exercise price of $30.86; the subsequent sale at $65.00 realizes the intrinsic spread per share. The derivative record shows the options were exercisable on 10/03/2025 and are set to expire on 01/03/2026, suggesting near-term option lifecycle activity.

Watch for additional exercises or sales before the 01/03/2026 expiration and for any company disclosures about equity plan grants that could affect dilution or executive compensation reporting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jacobson Allan Steven

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/03/2025		M(1)		12,000	A	$30.86	29,451	D
Common Stock	10/03/2025		S(1)		12,000	D	$65	17,451	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.86	10/03/2025		M(1)			12,000	(2)	01/03/2026	Common Stock	12,000	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 12, 2025.

2. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.